Evidence map›Paper›PMID 31719169›Full record

ArticleJournal of medical genetics2020

Psychosocial effects of whole-body MRI screening in adult high-risk pathogenic

Elizabeth K Bancroft, Sibel Saya, Emma Brown, Sarah Thomas, Natalie Taylor, Jeanette Rothwell, Jennifer Pope, Anthony Chamberlain, Elizabeth Page, Sarah Benafif and 23 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of medical genetics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Guideline
  2. Trial
  3. Observational
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Whole-body MRI for cancer surveillance in ataxia-telangiectasia: A qualitative study of the perspectives of people affected by A-T and their families.Health expectations : an international journal of public participation in health care and health policy · 2023
    Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors at 17 institutions in 2 countries.

Elizabeth K BancroftOncogenetics Team, The Royal Marsden NHS Foundation Trust, London, UK elizabeth.bancroft@rmh.nhs.uk.ORCID 0000-0002-5482-5660
Sibel SayaOncogenetics Team, The Institute of Cancer Research, London, UK.ORCID 0000-0002-4796-6852
Emma BrownMedical Oncology, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
Sarah ThomasOncogenetics Team, The Royal Marsden NHS Foundation Trust, London, UK.
Natalie TaylorOncogenetics Team, The Royal Marsden NHS Foundation Trust, London, UK.
Jeanette RothwellClinical Genetics, Manchester University NHS Foundation Trust, Manchester, UK.
Jennifer PopeOncogenetics Team, The Institute of Cancer Research, London, UK.
Anthony ChamberlainOncogenetics Team, The Institute of Cancer Research, London, UK.
Elizabeth PageOncogenetics Team, The Institute of Cancer Research, London, UK.
Sarah BenafifOncogenetics Team, The Institute of Cancer Research, London, UK.
Helen HansonSouth West Thames Regional Genetics Service, St Georges NHS Foundation Trust, London, UK.
Alexander DiasOncogenetics Team, The Institute of Cancer Research, London, UK.
Christos MikropoulosSt Luke's Cancer Centre, Royal Surrey County Hospital, Guildford, UK.
Louise IzattClinical Genetics, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Lucy SideClinical Genetics, Wessex Clinical Genetics Service, Southampton, UK.
Lisa WalkerClinical Genetics, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Alan DonaldsonClinical Genetics, University Hospitals Bristol NHS Foundation Trust, Bristol, UK.
Jackie A CookDepartment of Clinical Genetics, Sheffield Children's Hospital, Sheffield, UK.
Julian BarwellClinical Genetics, University Hospitals of Leicester NHS Trust, Leicester, UK.
Vicki WilesClinical Genetics, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Lauren LimbNorth West Thames Regional Genetics Service (Kennedy-Galton Centre), London North West University Healthcare NHS Trust, Harrow, UK.
Diana M EcclesCancer Sciences, University of Southampton Faculty of Medicine, Southampton, UK.ORCID 0000-0002-9935-3169
Martin O LeachDepartment of Diagnostic Radiology, The Royal Marsden NHS Foundation Trust, London, UK.
Susan ShanleyFormerly at the Familial Cancer Centre, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Fiona J GilbertDepartment of Radiology, University of Cambridge, Cambridge, UK.
David GallagherCancer Genetics Service, Mater Hospital School, Dublin, Ireland.
Balashanmugam RajashankerRadiology, Manchester Royal Infirmary, Manchester, UK.
Richard W WhitehouseRadiology, Manchester Royal Infirmary, Manchester, UK.
Dow-Mu KohDepartment of Diagnostic Radiology, The Royal Marsden NHS Foundation Trust, London, UK.
S Aslam SohaibDepartment of Diagnostic Radiology, The Royal Marsden NHS Foundation Trust, London, UK.
D Gareth EvansClinical Genetics, Manchester University NHS Foundation Trust, Manchester, UK.ORCID 0000-0002-8482-5784
Rosalind A EelesOncogenetics Team, The Royal Marsden NHS Foundation Trust, London, UK.
Leslie G WalkerPostgraduate Medical Studies, University of Hull, Hull, UK.
Royal Marsden NHS Foundation Trust · GBInstitute of Cancer Research · GBManchester Royal Infirmary · GBManchester University NHS Foundation Trust · GBUniversity of Hull · GBCambridge University Hospitals NHS Foundation Trust · GBGuy's and St Thomas' NHS Foundation Trust · GBLondon North West Healthcare NHS Trust · GBPeter MacCallum Cancer Centre · AURoyal Surrey County Hospital · GBSheffield Children's Hospital · GBUniversity Hospitals Bristol NHS Foundation Trust · GBUniversity Hospitals of Leicester NHS Trust · GBUniversity Hospital Southampton NHS Foundation Trust · GBUniversity of Cambridge · GBUniversity of Southampton · GBWessex Regional Genetics Laboratory · GB

Funding

Cancer Research UK 16464Cancer Research UK C1060/A16464
6 · The paper itself

Abstract

backgroundGermline

methodsPsychosocial and other assessments were carried out at study enrolment, immediately before MRI, before and after MRI results, and at 12, 26 and 52 weeks' follow-up.

resultsWB-MRI was found to be acceptable with high levels of satisfaction and low levels of psychological morbidity throughout. Although their mean levels of cancer worry were not high, carriers had significantly more cancer worry at most time-points than controls. They also reported significantly more clinically significant intrusive and avoidant thoughts about cancer than controls at all time-points. There were no clinically significant adverse psychosocial outcomes in either carriers with a history of cancer or in those requiring further investigations.

conclusionWB-MRI screening can be implemented in

Indexed as

Magnetic Resonance ImagingAdultFemaleGenetic Predisposition to DiseaseGerm-Line MutationHeterozygoteHumansLi-Fraumeni SyndromeMaleMiddle AgedNeoplasmsRisk FactorsTumor Suppressor Protein p53Whole Body ImagingYoung AdultTP53 protein, humanTumor Suppressor Protein p53case controlled studyLi-Fraumeni syndromeMRIpsychosocialTP53 gene pathogenic variant

Identifiers

PMID31719169
PMCPMC7146942
OpenAlexW2979352829

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.